<DOC>
	<DOCNO>NCT03010982</DOCNO>
	<brief_summary>This Phase 1 , open-label , two-part study design characterize PK IV dose approximately 12 µg tazemetostat contain approximately 500 nCi [ 14C ] tazemetostat ADME oral dose 800 mg tazemetostat contains approximately 400 µCi [ 14C ] -labeled tazemetostat three subject B-cell lymphoma .</brief_summary>
	<brief_title>An Open-Label , Single-Center , Two-Part , Phase 1 Study Characterize Pharmacokinetics Intravenous Micro-Dose 14C-Tazemetostat ( EPZ 6438 ) Absorption , Distribution , Metabolism Elimination Oral 14C-Labeled Dose Tazemetostat Subjects With B-Cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Male ≥ 18 year age time consent 2 . Female ≥ 18 year age time consent nonchildbearing potential A woman consider nonchildbearing potential reach postmenopausal state ( ≥ 12 continuous month amenorrhea identify cause menopause ) undergone surgical sterilization ( removal ovary and/or uterus ) . Note : Postmenopausal state confirm FSH test complete screening period . 3 . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 4 . Has life expectancy &gt; 3 month 5 . Has histologically confirm Bcell lymphomas include limit diffuse large Bcell lymphoma ( DLBCL ) , follicular lymphoma ( FL ) , primary mediastinal Bcell lymphoma ( PMBCL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) , Hodgkin lymphoma ( HL ) relapse refractory disease follow least two line prior standard therapy , include alkylator/anthracycline ( unless anthracyclinebased chemotherapy contraindicate ) /antiCD20based therapy ( RCHOP , rituximab , doxorubicin , cyclophosphamide , vincristine , prednisolone dexamethasone , equivalent nonHodgkin lymphoma ) , AND must consider unable benefit intensification treatment autologous hematopoietic stem cell transplantation ( ASCT ) , define meeting least one follow criterion : Relapsed following , refractory , previous ASCT Did achieve least partial response standard salvage regimen ( e.g. , RICE , rituximab , ifosfamide , carboplatin , etoposide , RDHAP , rituximab , dexamethasone , cytarabine , cisplatin ) Ineligible intensification treatment due age significant comorbidity Ineligible intensification treatment due failure mobilize acceptable number hematopoietic stem cell Refused intensification treatment and/or ASCT 6 . May evaluable measurable disease 7 . Has prior treatment ( i.e. , chemotherapy , immunotherapy , radiotherapy ) relate clinically significant toxicity resolve ≤ Grade 1 per CTCAE , version 4.03 clinically stable , time consent 8 . Time last dose late therapy first dose study drug : 1 . Chemotherapy : cytotoxic least 21 day 2 . Chemotherapy : nitrosureas least 6 week 3 . Chemotherapy : noncytotoxic ( e.g . small molecule inhibitor ) least 14 day 4 . Monoclonal antibody ( y ) least 28 day 5 . Immunotherapy ( e.g . tumor vaccine ) least 28 day 6 . Radiotherapy ( RT ) least 14 day local site RT , least 21 day stereotactic radiosurgery , least 12 week craniospinal , ≥50 % radiation pelvis , total body irradiation 7 . High dose therapy autologous hematopoietic cell infusion least 60 day 8 . Hematopoietic growth factor least 14 day 9 . Has adequate hematologic ( bone marrow [ BM ] coagulation factor ) , renal hepatic function define criterion : 1 . Hemoglobin ≥9 g/dL 2 . Platelet ≥75,000/mm3 ( ≥75 × 10^9/L ) 3 . ANC ≥750/mm3 ( ≥0.75 × 10^9/L ) 4 . PT &lt; 1.5 ULN 5 . PTT &lt; 1.5 ULN 6 . Creatinine &lt; 2.0 ULN 7 . Conjugated bilirubin &lt; 1.5 × ULN 8 . AST &lt; 3 × ULN I. ALT &lt; 3 × ULN NOTE : Laboratory result obtain screen use determine eligibility criterion . In situation laboratory result outside permitted range , investigator may retest subject subsequent within range screen result may use determine subject 's eligibility 10 . Subjects history Hepatitis B C eligible condition subject adequate liver function define protocol hepatitis B surface antigen negative and/or undectable HCV RNA . 11 . Has QT interval correct Fridericia 's formula ( QTcF ) ≤480 msec 12 . Subject must regular bowel movement ( minimum 1 bowel movement every day every day ; 3 bowel movement per day ) past 2 week without diarrhea ( &gt; 4 bowel movement per day ) constipation ( few 3 bowel movement 1 week ) . No known medical history disease syndrome affect bowel function ( e.g. , irritable bowel syndrome , inflammatory bowel disease , ulcerative colitis , etc . ) , fecal incontinence , history significant opioid induce constipation within past 3 month 13 . Subject must ability regularly void urine current evidence urinary incontinence , urinary retention , uncorrected congenital defect interfere normal urinary system function , chronic urinary tract infection , condition may interfere normal urinary bladder empty . In past 3 month , obstructive uropathy , surgery affect urinary system ( e.g. , radical prostatectomy , TURP , etc . ) , urinary tract infection . Subjects solitary kidney exclude study 14 . Male subject must refrain donate sperm start plan first dose study drug 30 day follow last dose study drug . Male subject female partner childbearing potential must vasectomize , remain abstinent use condom define Section 8.3.8 , start plan first dose study drug 30 day follow last dose study drug . The reliability sexual abstinence evaluate relation duration clinical trial prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Female partner male subject childbearing potential must also adhere one following : Placement intrauterine device intrauterine system . Established use oral , injected implant hormonal method contraception . Progesterone oral contraception , inhibition ovulation primary mode action . Subjects meet ANY follow criterion must NOT enrol study : 1 . Has participate study [ 14C ] administer within last 6 month prior screen study 2 . Has CNS leptomeningeal metastasis 3 . Has prior malignancy malignancy study Exception : Subject diseasefree 3 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible 4 . Has major surgery within 3 week prior enrollment NOTE : Minor surgery ( e.g. , minor biopsy , central venous catheter placement ) permit within 3 week prior enrollment 5 . Is unwilling exclude grapefruit juice , Seville oranges grapefruit diet food contain fruits time enrollment study 6 . Has cardiovascular impairment , history congestive heart failure great NYHA Class II uncontrolled arterial hypertension , unstable angina , myocardial infarction , stroke within 6 month prior plan first dose tazemetostat ; ventricular cardiac arrhythmia require medical treatment 7 . Subjects take medication know potent CYP3A4 inducers/inhibitors ( include St. John 's Wort ) 14 day prior first dose study medication ( see http : //www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm ; http : //medicine.iupui.edu/clinpharm/ddis/ list potent CYP3A4 inducer inhibitor ) . 8 . Has active infection require systemic treatment 9 . Is immunocompromised , include subject know history infection human immunodeficiency virus ( HIV ) 10 . Has know history chronic infection hepatitis B virus ( hepatitis B surface antigen positive ) hepatitis C virus ( detectable HCV RNA ) 11 . Has venous thrombosis pulmonary embolism within 3 month prior study enrollment . NOTE : Subjects history deep vein thrombosis &gt; 3 month prior study enrollment anticoagulation therapy low molecular weight heparin eligible study . 12 . Has know hypersensitivity component study drug 13 . Is unable take oral medication , malabsorption syndrome uncontrolled gastrointestinal condition ( e.g. , nausea , diarrhea vomit ) might impair bioavailability study drug 14 . Has uncontrolled intercurrent illness include , limited , uncontrolled infection , psychiatric illness/social situation would limit compliance study requirement 15 . Is unwilling adhere contraception criterion time enrollment study least 30 day last dose study drug 16 . Clinical history , current alcohol ( ethanol ) , illicit drug use , judgment investigator , interfere subject 's ability comply dose schedule protocolspecified evaluation 17 . A history bleeding ( i.e. , hemoptysis , hematuria , GI blood loss , epistaxis , others great Grade 1 accord National Cancer Institute Common Terminology Criteria Version 4.0 [ NCICTC v4.0 ] ) within 1 month prior begin therapy clinical indication current active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>